Key Takeaways
- India business turns a corner: After roughly six quarters of decline, India revenue and margins rose sequentially, driven by a recovery in glass-lined equipment (GLE) volumes and pricing, plus cost actions.
- Diversification is now the growth engine: Heavy engineering, mixing, and non-chemical/pharma verticals (oil & gas, metals, semiconductors) are filling the hole left by weak agrochemicals, with management explicitly targeting a reduction in chemical and pharma exposure to 50% of revenue.
- International business lags, footprint rationalization underway: International revenue dipped sequentially and faces continued softness, especially in China. The response is structural: Poland manufacturing is live, the UK footprint is gone, and the long-term goal is to shift production from high-cost Western countries to India and lower-cost European sites.
- Margins improved 300 bps sequentially but caution remains: Cost consolidation (Gujarat, Hyderabad closure, UK rationalization) and returning GLE volumes helped, but management warns they are "not out of the woods yet" and declined to quantify next year's EBITDA margin target.
- What to watch next quarter: Whether the agrochemical investment cycle actually restarts "over the next couple of quarters," the pace of international margin recovery as manufacturing shifts to lower-cost sites, and any quantification of the long-term strategic plan promised in the next financial year.
India Turnaround: What Recovered and Why
- GLE volumes and pricing stabilize: After consecutive quarterly declines, GLE saw both volume and price recovery. All production is now consolidated into the single Gujarat facility, which previously ran two sites at 60% utilization, improving cost absorption and efficiency going forward.
- Non-GLE backlog strengthens: Improved backlog in mixing, heavy engineering, and solid-liquid separation businesses contributed to the India revenue uptick, alongside cost improvement actions taken over recent quarters.
- Revenue held flat despite a ~₹300–400 crore agrochemical hole: Three large agrochemical customers pulled back significantly, yet overall revenue stayed level because new business from oil & gas, petrochemicals, and similar industries compensated. This validates the diversification push but also underscores how deep the agrochemical drag was.
- Services push as a margin lever: Growing the services business in India is a stated priority; since services carry higher margins than original equipment, a mix shift toward services should improve the margin profile on a sustainable basis, though management declined to quantify the impact.
Tarak Patel: "I would just caution you to think about as I said, things are looking better. Things are looking more positive. Some volumes are coming back, prices are improving. But again, if you ask me are we out of the woods, yet I would still be a little bit more conservative."
Diversification: Breaking the Chemical and Pharma Dependence
- The strategic learning: Management now views its historical concentration in chemicals and pharma as a vulnerability, given the cyclicality those end-markets carry. Diversification into new products and new industry segments is the stated path to double-digit growth.
- Where the new revenue is coming from: Heavy engineering has broken through in oil & gas and petrochemicals; mixing has broken through in metals & minerals; Edlon (the US subsidiary) is improving via the semiconductor industry. Other new verticals include wastewater and paints.
- Heavy engineering scaling fast: Heavy engineering has grown significantly and will grow again this year; it was a much smaller share of total revenue last year and will be a meaningfully larger share this year, though management declined to provide a segment-level order inflow breakup.
- Revenue mix target: Chemical and pharma exposure is expected to reduce to 50% of revenue "in the next couple of years," with real growth coming from the new industries.
- GLE market is structurally capped: Glass-lined equipment is a stable business with a market size that will not grow significantly more, and GMM Pfaudler already holds roughly 50% market share, making further share gains tough. Growth must come from non-GLE businesses and new verticals.
Tarak Patel: "One of the main learning for management over the last couple of years has been that maybe as a company we are too focused on chemicals and pharma. And, with the cyclicality that comes with these markets, diversification becomes an important part of our strategy."
International Business: Softness and Structural Fixes
- Sequential revenue decline, slower recovery expected: International revenues dipped slightly quarter-on-quarter, and management expects the slowdown to persist a bit longer than in India. China, where GMM Pfaudler has a strong glass-lined business, is a particular headwind, though non-GLE international units are performing well.
- Poland manufacturing is live: The Poland investment agreement has been executed, two orders have already been manufactured there with good quality levels, and a third order is now being planned. This shifts production out of higher-cost Western European sites.
- UK manufacturing footprint eliminated: The UK facility has been rationalized and is no longer in the mix, a move expected to improve efficiencies in the remaining German and Italian operations.
- Long-term manufacturing vision: The goal is to reduce manufacturing in high-cost countries (US, Western Europe), ramp up India to supply the rest of the world, and use Brazil and China as low-cost manufacturing bases for glass-lined products. Some sites in Europe and the US will be retained for services, with less focus on new manufacturing there.
Tarak Patel: "When you buy a GMM Pfaudler reactor anywhere in the world, you should not really worry where it is made. At the end of the day, you get the right quality, you get the right price, and you get the right timeframe in terms of delivery."
Order Book and Revenue Conversion
- Order intake stable, not accelerating: Order intake remains "pretty stable" but has not returned to the levels of a couple of years ago. Management acknowledged it is "a few crores or few points lower" but did not directly address the apparent deceleration from 18–20% growth in H1 to 6–7% this quarter.
- Revenue flatness explained by mix shift, not execution issues: Despite a strong order book of roughly ₹1,600 crores in the first two quarters, revenue stayed flat because large systems orders take about a year to ship out, while the product mix is shifting from shorter-cycle glass-lined equipment to longer-cycle systems orders. Management stated "nothing went wrong" on execution.
- Test center inaugurated in Karamsad: A new test center at the Gujarat facility, mirroring similar centers in Europe and North America, allows customers to run trials on reaction, concentration drying, and wiped film evaporation. Customer trials have already started, which could support future order conversion.
Cost and Margin Trajectory
- 300 bps sequential margin improvement: Consolidated and standalone margins both improved, driven by GLE volume recovery, price improvement, and cost actions.
- Cost actions already executed: The Hyderabad facility (acquired from De Dietrich roughly three years ago) has been shut down and production consolidated into Gujarat. The UK manufacturing footprint has been rationalized. A McKinsey-led cost project is in its final stage.
- Hyderabad facility on hold, not divested: The site is mothballed rather than sold; management would restart it if volumes return or a new product line needs the capacity.
- Other income boost from FX: Other income of ₹25 crores came primarily from a foreign exchange gain as the Euro depreciated, creating an inter-company mark-to-market benefit.
- Next-year margin ambition is directional, not quantified: Management wants to improve both EBITDA margin and absolute EBITDA volume for the next financial year, but said putting a specific number on it now is difficult. The long-term aspiration is a 15% margin profile across businesses, with technology products at or above that level.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Agrochemical investment recovery | Investment to return, outlook more positive than six months ago | "Over the next couple of quarters" |
| Chemical and pharma full turnaround | Full turnaround in these end-markets | "A few more quarters" |
| Revenue mix target | Chemical and pharma exposure to reduce to 50% of revenue | "Next couple of years" |
| International near-term trajectory | Next quarter remains more or less like the last one | Next quarter |
| Long-term strategic plan | 3–4 year plan to be articulated to capital markets; currently 60–70% agreed upon, top management meeting planned next month | "Next financial year" |
| Manufacturing footprint shift | Reduce manufacturing in high-cost countries, ramp up India, use Brazil and China for low-cost glass-lined production | Ongoing, "not quite there yet" |
| EBITDA margin | Improve both margin percentage and absolute EBITDA volume vs current year | Next financial year (no number given) |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹801 cr, stable QoQ |
| EBITDA | Up 3% QoQ |
| EBITDA margin | 12%, improved from 11.6% in Q2 FY25 |
| EBITDA margin guidance | 11% to 12% for full year FY25 |
| Order intake | ₹798 cr, up 5% QoQ |
| Order intake growth | 6% to 7% YoY across India and international, vs 18% to 20% in H1 FY25 |
| 9M order intake | ₹2,442 cr, up 13% vs 9M FY24 |
| Order backlog | ₹1,740 cr, up 7% vs December 31, 2023 |
| India standalone revenue | Down 8% YoY |
| Revenue from chemical and pharma | 70% to 80% of total revenue |
| Services business share | 35% to 40% of international business, single digit in India |
| Mixing business share | 10% to 12% of total revenue in Q3 and 9M FY25 |
| Heavy engineering growth | Double digit growth in 9M FY25 |
| Net debt | ₹450 cr as of September 2024 balance sheet, with ₹950 cr debt and ₹400 cr cash |
| Net finance cost | ₹70 to 80 cr |
| Net debt cost | Less than 8% India and international combined |
| Other income | ₹25 cr in Q3 FY25, primarily on account of FX gain |
| Target margin profile | 15% across businesses |